Department of Experimental Medicine and Public Health, University of Camerino, 62032 Camerino, Macerata, Italy.
Alcohol. 2009 Nov;43(7):491-8. doi: 10.1016/j.alcohol.2009.08.003.
This article summarizes the proceedings of a symposium held at the conference on "Alcoholism and Stress: A Framework for Future Treatment Strategies" in Volterra, Italy, May 6-9, 2008. Chaired by Markus Heilig and Roberto Ciccocioppo, this symposium offered a forum for the presentation of recent data linking neuropetidergic neurotransmission to the regulation of different alcohol-related behaviors in animals and in humans. Dr. Donald Gehlert described the development of a new corticotrophin-releasing factor receptor 1 antagonist and showed its efficacy in reducing alcohol consumption and stress-induced relapse in different animal models of alcohol abuse. Dr. Andrey Ryabinin reviewed recent findings in his laboratory, indicating a role of the urocortin 1 receptor system in the regulation of alcohol intake. Dr. Annika Thorsell showed data supporting the significance of the neuropeptide Y receptor system in the modulation of behaviors associated with a history of ethanol intoxication. Dr. Roberto Ciccocioppo focused his presentation on the nociceptin/orphanin FQ (N/OFQ) receptors as treatment targets for alcoholism. Finally, Dr. Markus Heilig showed recent preclinical and clinical evidence suggesting that neurokinin 1 antagonism may represent a promising new treatment for alcoholism. Collectively, these investigators highlighted the significance of neuropeptidergic neurotransmission in the regulation of neurobiological mechanisms of alcohol addiction. Data also revealed the importance of these systems as treatment targets for the development of new medication for alcoholism.
本文总结了 2008 年 5 月 6 日至 9 日在意大利沃尔泰拉举行的“酒精中毒和应激:未来治疗策略框架”会议上的一次专题讨论会的会议记录。本次专题讨论会由 Markus Heilig 和 Roberto Ciccocioppo 共同主持,为展示将神经肽能神经传递与动物和人类不同的酒精相关行为的调节联系起来的最新数据提供了一个论坛。Donald Gehlert 博士描述了一种新的促肾上腺皮质素释放因子受体 1 拮抗剂的开发,并展示了其在减少不同酒精滥用动物模型中的酒精消耗和应激诱发复发方面的功效。Andrey Ryabinin 博士回顾了他实验室的最新发现,表明 Urocortin 1 受体系统在调节酒精摄入方面发挥作用。Annika Thorsell 博士展示的数据支持神经肽 Y 受体系统在调节与乙醇中毒史相关行为方面的重要性。Roberto Ciccocioppo 博士将他的演讲重点放在了伤害感受素/孤啡肽(N/OFQ)受体作为治疗酒精中毒的靶点上。最后,Markus Heilig 博士展示了最近的临床前和临床证据,表明神经激肽 1 拮抗可能是治疗酒精中毒的一种有前途的新方法。这些研究人员共同强调了神经肽能神经传递在调节酒精成瘾的神经生物学机制中的重要性。这些数据还揭示了这些系统作为治疗靶点的重要性,以便为开发新的酒精中毒药物提供新的药物。